Overview
Clinical Updates in Chronic Myeloid Leukemia: New Understandings in Disease Diagnosis, Monitoring and Personalized Therapeutic Regimens Utilizing Tyrosine Kinase Inhibitors
CML Expert Perspectives
Click the"View Activity" button to view this activity.
View ActivityCME/CE is no longer available for this activity
Advance your understanding on how to better diagnose, treat, and monitor CML. Expert faculty from MD Anderson recently gave a series of lectures across the country on the latest research and treatment regimen recommendations in CML. Highlighting key takeaways from this meeting series, faculty review the role of ABL tyrosine kinase inhibitor (TKI) agents in advancing treatment and delivering up-to-date care as well as discuss safety and tolerability of various TKIs in CML. They examine practical clinical strategies for managing potential toxicities resulting from treatment as well as optimizing health outcomes by personalizing treatment regimens based on patient-centered needs and disease characteristics.
This expert roundtable includes downloadable resources to improve care for your CML patients featuring key summary points and includes slides from the national visiting lecture series.
This expert roundtable includes downloadable resources to improve care for your CML patients featuring key summary points and includes slides from the national visiting lecture series.
This is a targeted activity to increase physician awareness and the application of clinical evidence to develop personalized treatment strategies to optimize the care of patients with CML.
Advance your understanding on how to better diagnose, treat, and monitor CML. This expert roundtable includes downloadable resources including key summary points and slides from the visiting lecture series.
At the conclusion of this educational activity, the participant should be able to:
• Review and discuss clinical considerations, including patient comorbidities, tolerability and safety profiles for frontline CML therapy options. (Knowledge, Competence)
• Describe current guideline recommendations for disease monitoring response to therapy in CML and considerations for TKI discontinuation in appropriate patients. (Knowledge, Competence, Performance)
• Understand strategies for managing treatment-related adverse events and drug-to-drug interactions associated with TKIs in patients with CML. (Knowledge)
• Review and discuss clinical considerations, including patient comorbidities, tolerability and safety profiles for frontline CML therapy options. (Knowledge, Competence)
• Describe current guideline recommendations for disease monitoring response to therapy in CML and considerations for TKI discontinuation in appropriate patients. (Knowledge, Competence, Performance)
• Understand strategies for managing treatment-related adverse events and drug-to-drug interactions associated with TKIs in patients with CML. (Knowledge)
Sponsored by the University of Texas MD Anderson Cancer Center and the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Pfizer, Inc.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
7. Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
• Acquired knowledge on evaluating patients’ health status and recognizing therapeutic options in regards to patient profiles. (Knowledge, Competence)
• Enhanced knowledge of efficacy and tolerability, patient monitoring management, tied to available therapeutic regimes along with increased awareness of guideline recommendations. (Knowledge, Competence)
• Clinicians will be informed of the different TKIs available for frontline treatment along with their unique toxicity profiles/drug-drug interactions leading to better patient monitoring and controlling adverse effects. (Knowledge, Competence, Performance)
• Enhanced knowledge of efficacy and tolerability, patient monitoring management, tied to available therapeutic regimes along with increased awareness of guideline recommendations. (Knowledge, Competence)
• Clinicians will be informed of the different TKIs available for frontline treatment along with their unique toxicity profiles/drug-drug interactions leading to better patient monitoring and controlling adverse effects. (Knowledge, Competence, Performance)
Naval Daver, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Michael Deininger, MD, PhD
M.M. Wintrobe Professor of Medicine
Chief of Hematology & Hematologic Malignancies
Department of Internal Medicine
University of Utah, Huntsman Cancer Institute
Salt Lake City, UT
Javier Pinilla-Ibarz, MD, PhD
Senior Member
Department of Malignant Hematology
H. Lee Moffitt Cancer Center and Research Institute
Tampa, FL
Elias J. Jabbour, MD
Associate Professor
Department of Leukemia
Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center
Houston, TX
Michael J. Mauro, MD
Professor of Medicine
Leader, Myeloproliferative Neoplasms Program
Leukemia Service
Memorial Sloan Kettering Cancer Center
New York, NY
Jerald Radich, MD
Professor, University of Washington School of Medicine
Member, Clinical Research Division, Fred Hutchinson Cancer Research Center
Seattle Washington Cancer Center
Seattle, WA
The Accreditation Council for Continuing Medical Education has announced standards and guidelines to insure that individuals participating in CME activities are aware of program chair(s), planning committee members, faculty/teacher/ authors, CME activity reviewer’s relationships with commercial interests that could potentially affect the information presented. The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest.
The University of Texas MD Anderson Cancer Center has, through a formal review process, resolved all conflicts of interest prior to this activity. For information on this process, please contact CME/Conference Management at (713) 792-5357.
The following Faculty, Program Planning Committee Members and CME Activity Reviewers/Approvers have financial interests, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financially support this CME activity, as indicated below. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.
The University of Texas MD Anderson Cancer Center has, through a formal review process, resolved all conflicts of interest prior to this activity. For information on this process, please contact CME/Conference Management at (713) 792-5357.
The following Faculty, Program Planning Committee Members and CME Activity Reviewers/Approvers have financial interests, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financially support this CME activity, as indicated below. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.
FACULTY | COMMERCIAL INTEREST |
Naval Daver, MD* | Grant or research support: Bristol-Myers Squibb, Pfizer, Novartis, Servier Laboratories, Novabay Pharmaceuticals, Daiichi Sankyo, Incyte; Honoraria: Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, Novartis, Otsuka Pharmaceutical, Servier Laboratories, Incyte |
Michael Deininger, MD, PhD | Grant or research support: Novartis, Pfizer; Paid consultant: Norvartis, Pfizer; Membership on advisory committees: Blueprint, Novartis, Pfizer |
Javier Pinilla-Ibarz, MD, PhD | Paid consultant: Norvartis, Takeda, Pfizer; Speaker’s Bureau: Takeda |
Elias J. Jabbour, MD* | Grant or research support: Amgen, Pfizer, Novartis, AbbVie, Bristol-Myers Squibb, Takeda |
Michael J. Mauro, MD | Grant or research support: Novartis; Membership on advisory committees: Bristol-Myers Squibb, Novartis, Takeda, Pfizer |
Jerald Radich, MD | Grant or research support: Novartis; Paid consultant: Norvartis |
PLANNING COMMITTEE MEMBERS | COMMERCIAL INTEREST |
Naval Daver, MD | Grant or research support: Bristol-Myers Squibb, Pfizer, Novartis, Servier Laboratories, Novabay Pharmaceuticals, Daiichi Sankyo, Incyte; Honoraria: Daiichi Sankyo, Bristol-Myers Squibb, Pfizer, Novartis, Otsuka Pharmaceutical, Servier Laboratories, Incyte |
Elias J. Jabbour, MD | Grant or research support: Amgen, Pfizer, Novartis, AbbVie, Bristol-Myers Squibb, Takeda |
CME ACTIVITY REVIEWERS/APPROVERS | COMMERCIAL INTEREST |
Issa Khouri, MD | Grant or research support: Pharmacyclics, Novartis, Paid Consultant: TRM Oncology |
Kenneth Rolston, MD | Grant or research support: Merck Inc., JMI Laboratories, Allergan; Membership on advisory committee or review panels, board membership, etc.: Allergan |
The following Faculty/Program Planning Committee Members and CME Activity Reviewers/Approvers HAVE INDICATED THEY HAVE NO FINANCIAL INTERESTS, arrangements or affiliations with the manufacturer of any product or devices to be discussed, or who may financial support this CME activity. An asterisk (*) indicates that the faculty’s presentation will include discussion of investigational or off-label uses of a product.
PLANNING COMMITTEE MEMBERS | |||
Mansour Alfayez, MD | Michelle Forcier | Arman Nabatiyan | Greg Paladino |
CME ACTIVITY REVIEWERS/APPROVERS | |||
Diane C. Bodurka, MD, BS, MPH | Pei Lin, MD |
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
Certificates awarding AMA PRA Category 1 CreditTM or certificates documenting participation will be issued immediately to participants when an individual completes the post-test and evaluation.
Non-Physicians will receive a certificate of participation in accordance with state nursing boards, specialty societies, or other professional associations.
Non-Physicians will receive a certificate of participation in accordance with state nursing boards, specialty societies, or other professional associations.
The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Texas MD Anderson Cancer Center designates this enduring material activity for a maximum of .50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The University of Texas MD Anderson Cancer Center designates this enduring material activity for a maximum of .50 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.